Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?

C Aggarwal, N Somaiah, G Simon - Cancer biology & therapy, 2012 - Taylor & Francis
Several therapies targeting angiogenesis are currently in development for non-small cell
lung cancer (NSCLC). This review discusses results of recent clinical trials evaluating …

[HTML][HTML] Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

[HTML][HTML] Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results

WW Tseng, N Somaiah, AJ Lazar, DC Lev, RE Pollock - Cancers, 2013 - mdpi.com
Liposarcoma is one of the most common adult soft tissue sarcomas an consists of three
histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery …

[HTML][HTML] Immuno-genomic landscape of osteosarcoma

CC Wu, HC Beird, J Andrew Livingston… - Nature …, 2020 - nature.com
Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune
checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors …

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

N Somaiah, AP Conley, ER Parra, H Lin… - The Lancet …, 2022 - thelancet.com
Background Few standard treatment options are available for patients with metastatic
sarcomas. We did this trial to evaluate the efficacy, safety, and changes in the tumour …

Universal marker and detection tool for human sarcoma circulating tumor cells

A Satelli, A Mitra, JJ Cutrera, M Devarie, X Xia… - Cancer research, 2014 - AACR
To date, no specific marker exists for the detection of circulating tumor cells (CTC) from
different types of sarcomas, though tools are available for detection of CTCs in peripheral …

Definition of pRB-and p53-dependent and-independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci

X Ye, B Zerlanko, R Zhang, N Somaiah… - … and cellular biology, 2007 - Am Soc Microbiol
Cellular senescence is an irreversible proliferation arrest triggered by short chromosome
telomeres, activated oncogenes, and cell stress and mediated by the pRB and p53 tumor …

[HTML][HTML] Molecularly targeted therapies in non–small-cell lung cancer annual update 2014

D Morgensztern, MJ Campo, SE Dahlberg… - Journal of Thoracic …, 2015 - Elsevier
There have been significant advances in the understanding of the biology and treatment of
non–small-cell lung cancer (NSCLC) during the past few years. A number of molecularly …

[HTML][HTML] Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

R Groisberg, DS Hong, A Behrang, K Hess… - … for immunotherapy of …, 2017 - Springer
Background Immunotherapies, specifically those based on immune checkpoint inhibitors,
have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) …

acccaaaccMDM2-p53 in Liposarcoma: The Need for Targeted Therapies With Novel Mechanisms of Action

N Somaiah, W Tap - Cancer Treatment Reviews, 2023 - Elsevier
Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors
that arise from lipocytes in soft tissue. There is a high unmet need in patients with these …